New meds coming out

[Mmorgan854]

I was wondering if anyone would know if I'm eligible for new meds coming out in the fall.  I'm hopeful I will be hep-c free with sol/RIBA but I'm being realistic that not all people clear.  I'm GT 2.  I thought I read a post that new meds are not for GT 2.  Just wondering if i will have an option for a backup plan, just in case.  Thanks in advance. Mary

[flyinlynn]

The quote was one week lead in did not provide any benefit "compared with 24 weeks of sofosbuvir and daclatasvir (SVR 100%)."

Although the 100% just refers to the number of patients in that trial group as they say individual results will vary. But yes I would think they could be considering 24 weeks of Sovaldi (trademark name drug name sofosbuvir) daclatasvir only time will tell the exact treatment regime that will recommended once the meds are released for availability by prescription. Ask him if he has heard about Sovaldi daclatasvir . I was trying to get into a clinical trial for that combo at the UW hepatology department before I was prescribed Sovaldi Olysio. A gastroenterologist may not be up to speed on all the new developments out there.

Surprised you haven't had a biopsy since 1995 my dr had me doing one every 5 years so I went from F1 in 1993 to F4 cirrhosis in 2008.

A non responder is someone who took the meds and it did not cure hep c interferon intolerant is someone who had to discontinue treatment due to side effects so I would go with intolerant. I completed 3 treatments with the either interferon monotherapy (3 shots a week of interferon with nothing else)  or interferon Ribavirin I was a non responder my viral load actually increased while I was on treatment. I am (or hopefully was) genotype 1a

Good luck hopefully you won't need this information as your treatment will work and you will be done

[Mmorgan854]

Thanks Lynn, the comment " one wk. lead-in w/ sofosbuvir ( solvaldi ? ) followed by 23 wks of dactastasvir an sofosbuvir ."  Would then be my back up plan if needed?  I am a bit confused.  Before I started tx. I asked the GI. Doctor what was available to me should this treatment not work.  He said , if I'm not mistaken, " nothing at this time for GT2 is recommended with new drugs coming out.  I have no idea if I have developed any degree of cirrhosis since the one an only time I had a biopsy in 1995 or so.  Was told mild activity at that point.  I also attempted treatment at that time with interferon but quit voluntarily after 4 mths due to severe depression an other side affects.  Was scheduled for 6 mths.  Not even sure if I would be considered non responder, intolerant, or other?  I thought since there are such knowledgable people on this forum , maybe someone knows something that my doctor doesn't concerning latest recommendations for GT2.  .. Thanks Hector an Jack for all your input.  Sorry, but still alittle confused.  Foggy??  Take care.  Mary

[flyinlynn]

Hi Hector

I was wondering about that 100% but that was what the reference Gastro journal had listed

Good luck on treatment Hector if anyone of us needs to beat hep c none more than you.

Best to you
Lynn

[HectorSF]

True not everyone is cured...but because you are infected with genotype 2 you have the best chance of anyone currently treating because genotype 2 virus is the easiest of genotypes to cure.

If you are treatment naive, according to the FISSION study you have a 97% chance of SVR if you don't have cirrhosis. That is as close to a 100% chance of cure as anyone has ever seen.

For those who did not achieve SVR with prior interferon-based treatment (treatment experienced) the FUSION study SVR rate for genotype 2 without cirrhosis is 90%.

Having genotype 2, you have the the highest odds of curing the virus as anyone currently treating does.

Hector

[flyinlynn]

Combination of Daclatasvir and Sofosbuvir for Hepatitis C Genotypes 1, 2, and 3

http://www.gastrojournal.org/article/S0016-5085%2814%2900777-X/fulltext

Among GT2 and 3, the overall SVR at week 12 (SVR-12) was 91% (GT2, 92%; GT3, 89%). This was similar in groups with (90%) or without RBV (86%). One week of lead-in with sofosbuvir followed by 23 weeks of daclatasvir and sofosbuvir did not provide any benefit (SVR 88%) compared with 24 weeks of sofosbuvir and daclatasvir (SVR 100%).

Bristol-Myers Squibb Submits NDAs for Daclatasvir and Asunaprevir to US FDA for the Treatment of Hepatitis C

http://news.bms.com/press-release/bristol-myers-squibb-submits-ndas-daclatasvir-and-asunaprevir-us-fda-treatment-hepatit

here you go
Lynn

[Sarah1949]

From HCV Guidelines - http://www.hcvguidelines.org/full-report/initial-treatment-hcv-infection-patients-starting-treatment

Recommended regimen for treatment-naive patients with HCV genotype 2, regardless of eligibility for IFN therapy:
Daily sofosbuvir (400 mg) and weight-based RBV (1000 mg [75 kg]) for 12 weeks is recommended for treatment-naive patients with HCV genotype 2 infection.

And

The following regimens are NOT recommended for treatment-naive patients with HCV genotype 2.
PEG/RBV for 24 weeks

Rating: Class IIb, Level A

Monotherapy with PEG, RBV, or a DAA

Rating: Class III, Level A

Telaprevir-, boceprevir-, or simeprevir-based regimens